自拟补气活血汤联合刮痧治疗医院获得性肺炎的临床观察

Clinical Efficacy of the Tonifying qi huoxue Soup Combined Gua Sha in the Treatment of Hospital Acquired Pneumonia

目的:研究自拟补气活血汤联合刮痧治疗医院获得性肺炎的临床疗效。方法:选择2015年1月至2015年12月医院获得性肺炎患者128例,按照随机数字表法分为对照组和治疗组,各64例。对照组给予静脉滴注哌拉西林他唑巴坦,治疗组在对照组基础上给予自拟补气活血汤联合刮痧。比较两组患者治疗14d后的临床疗效,检测治疗前、后C-反应蛋白(CRP)、氧合指数(PaO_2/FiO_2)、机械通气时间、抗生素使用时间、细菌清除率以及炎性因子的水平,记录不良反应的发生情况。结果:治疗14d后,治疗组总有效率为78.12%显著高于对照组的56.26%(P<0.05);两组患者各观察指标以及炎性因子的水平均较治疗前有改善(P<0.05),且治疗组改善程度显著大于对照组,组间差异有统计学意义(P<0.05);两组不良反应发生率均较低(P>0.05)。结论:自拟补气活血汤联合刮痧用于治疗医院获得性肺炎,能提高临床疗效、改善症状、促进恢复,且不良反应少,值得临床推广。

Objective： To study the clinical efficacy of the tonifying qi huoxue soup combined Gua Sha in the treatment of hospital acquired pneumonia. Methods： 128 cases of severe pneumonia patients were collected from January 2015 to December 2015,and randomly divided into treatment group and control group,64 cases in each group. The control group given intravenous infusion piperacillin-tazobactam,treatment group on the basis of control group to give the tonifying qi huoxue soup combined Gua Sha.Compare two groups of patients with the clinical curative effect of treatment for 14 days,test before and after treatment C-reactive protein（ CRP）,oxygenation index（ PaO2/FiO2） mechanical ventilation time,antibiotic use time,bacterial clearance rate and the level of inflammatory cytokines,record the occurrence of adverse reactions. Results：After treatment,the total effective rate was 78.12% in treatment group was significantly higher than 56.26%（ P〈0.05）;; each observed indicators in two groups and levels of inflammatory cytokines were improved than before treatment（ P〈0.05）,and the degree of improvement in the treatment group was significantly greater than in the control group,the difference was statistically significant（ P〈0.05）. The incidence of adverse reactions were very low in both groups（ P〉0.05）. Conclusion： the tonifying qi huoxue soup combined Gua Sha in the treatment of hospital acquired pneumonia,can improve the clinical curative effect,improve the symptoms and promote recovery,and less adverse reactions,worthy of clinical promotion.